Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Ono Pharmaceutical Co., Ltd. Snapshot | 7 | 1 |
| Ono Pharmaceutical Co., Ltd. Overview | 7 | 1 |
| Key Facts | 7 | 1 |
| Ono Pharmaceutical Co., Ltd. Research and Development Overview | 8 | 5 |
| Key Therapeutic Areas | 8 | 5 |
| Ono Pharmaceutical Co., Ltd. Pipeline Review | 13 | 7 |
| Pipeline Products by Stage of Development | 13 | 1 |
| Pipeline Products Monotherapy | 14 | 1 |
| Pipeline Products Combination Treatment Modalities | 15 | 1 |
| Pipeline Products Partnered Products | 16 | 1 |
| Partnered Products/Combination Treatment Modalities | 17 | 1 |
| Pipeline Products Out-Licensed Products | 18 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 19 | 1 |
| Ono Pharmaceutical Co., Ltd. Pipeline Products Glance | 20 | 6 |
| Ono Pharmaceutical Co., Ltd. Late Stage Pipeline Products | 20 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 20 | 1 |
| Phase III Products/Combination Treatment Modalities | 21 | 1 |
| Ono Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products | 22 | 1 |
| Phase II Products/Combination Treatment Modalities | 22 | 1 |
| Phase I Products/Combination Treatment Modalities | 23 | 1 |
| Ono Pharmaceutical Co., Ltd. Early Stage Pipeline Products | 24 | 1 |
| Preclinical Products/Combination Treatment Modalities | 24 | 1 |
| Discovery Products/Combination Treatment Modalities | 25 | 1 |
| Ono Pharmaceutical Co., Ltd. Drug Profiles | 26 | 73 |
| (carbidopa + levodopa prodrug) Drug Profile | 26 | 1 |
| abatacept Drug Profile | 27 | 5 |
| anamorelin hydrochloride Drug Profile | 32 | 4 |
| E-0001163 Drug Profile | 36 | 1 |
| etelcalcetide hydrochloride Drug Profile | 37 | 5 |
| ivabradine hydrochloride Drug Profile | 42 | 2 |
| landiolol Drug Profile | 44 | 1 |
| metyrosine Drug Profile | 45 | 1 |
| Monoclonal Antibody for Autoimmune Disease Drug Profile | 46 | 1 |
| nivolumab Drug Profile | 47 | 30 |
| ONO-2952 Drug Profile | 77 | 1 |
| ONO-4059 Drug Profile | 78 | 2 |
| ONO-4127 Drug Profile | 80 | 1 |
| ONO-4232 Drug Profile | 81 | 1 |
| ONO-4310321 Drug Profile | 82 | 1 |
| ONO-4474 Drug Profile | 83 | 1 |
| ONO-7268MX1 Drug Profile | 84 | 1 |
| ONO-7268MX2 Drug Profile | 85 | 1 |
| ONO-8055 Drug Profile | 86 | 1 |
| ONO-8430506 Drug Profile | 87 | 1 |
| ONO-8577 Drug Profile | 88 | 1 |
| opicapone Drug Profile | 89 | 2 |
| oprozomib Drug Profile | 91 | 3 |
| salirasib Drug Profile | 94 | 2 |
| Small Molecule to Antagonize S1P2 Drug Profile | 96 | 1 |
| Small Molecule to Inhibit Protease Enzyme for Undisclosed Indication Drug Profile | 97 | 1 |
| Small Molecules to Antagonize Lysophosphatidic Acid Receptor 1 Drug Profile | 98 | 1 |
| Ono Pharmaceutical Co., Ltd. Pipeline Analysis | 99 | 8 |
| Ono Pharmaceutical Co., Ltd. Pipeline Products by Target | 99 | 3 |
| Ono Pharmaceutical Co., Ltd. Pipeline Products by Route of Administration | 102 | 1 |
| Ono Pharmaceutical Co., Ltd. Pipeline Products by Molecule Type | 103 | 1 |
| Ono Pharmaceutical Co., Ltd. Pipeline Products by Mechanism of Action | 104 | 3 |
| Ono Pharmaceutical Co., Ltd. Dormant Projects | 107 | 2 |
| Ono Pharmaceutical Co., Ltd. Discontinued Pipeline Products | 109 | 5 |
| Discontinued Pipeline Product Profiles | 111 | 1 |
| arundic acid | 111 | 1 |
| asimadoline | 111 | 1 |
| ceralifimod | 111 | 1 |
| freselestat | 111 | 1 |
| gemilukast | 111 | 1 |
| ipilimumab | 111 | 1 |
| limaprost | 111 | 1 |
| methylnaltrexone bromide | 112 | 1 |
| NIP-022 | 112 | 1 |
| ONO-1266 | 112 | 1 |
| ONO-2506-PO | 112 | 1 |
| ONO-4053 | 112 | 1 |
| ONO-4127 | 112 | 1 |
| ONO-5129 | 112 | 1 |
| ONO-5334 | 112 | 1 |
| ONO-6126 | 113 | 1 |
| ONO-8539 | 113 | 1 |
| remimazolam | 113 | 1 |
| rivenprost | 113 | 1 |
| tecemotide | 113 | 1 |
| Ono Pharmaceutical Co., Ltd. Locations And Subsidiaries | 114 | 3 |
| Head Office | 114 | 1 |
| Other Locations &Subsidiaries | 115 | 2 |
| Appendix | 117 | 2 |
| Methodology | 117 | 1 |
| Coverage | 117 | 1 |
| Secondary Research | 117 | 1 |
| Primary Research | 117 | 1 |
| Expert Panel Validation | 117 | 1 |
| Contact Us | 117 | 1 |
| Disclaimer | 118 | 1 |